Similar efficacy and safety between PG201 and SKI306X herbal medicines for knee OA .
Prospective, randomized, double-blinded, double-dummy and multicenter phase IV clinical study comparing the efficacy and safety of PG201 (Layla) and SKI306X in patients with osteoarthritis
J Ethnopharmacol. 2016 Apr 2;181:1-7124 patients with mild-to-moderate symptomatic knee osteoarthritis were randomized to daily treatment with tablets of either PG201, a 12-herb formulation, or SKI306X, a 3-herb formulation. The purpose of this study was to evaluate if PG201 demonstrated non-inferior efficacy and safety compared to SKI306X when assessed after 8 and 12 weeks. Efficacy parameters included a visual analog scale for pain, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score, the Euro Quality of Life 5 Dimensions questionnaire (EQ-5D), patient assessed symptom improvement, and rescue analgesia consumption. Adverse events and serious adverse events were monitored and documented. Results demonstrated no significant differences between groups in any efficacy or safety measure.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
